<DOC>
	<DOCNO>NCT01545687</DOCNO>
	<brief_summary>RATIONALE : Lactobacillus bevis CD2 lozenge may help prevent symptom mucositis , mouth sore , patient receive radiation therapy chemotherapy . This therapy may improve quality life patient head neck cancer . PURPOSE : This phase III trial study well Lactobacillus bevis CD2 lozenge prevents oral mucositis patient head neck cancer treat cisplatin radiation therapy . These result compare result patient use placebo lozenge .</brief_summary>
	<brief_title>CD2 Lozenges Preventing Acute Oral Mucositis Patients With Head Neck Cancer Receiving Radiotherapy Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine whether Lactobacillus brevis CD2 lozenge effective reduce oral mucositis ( OM ) -related pain patient undergoing chemoradiotherapy ( CRT ) head neck squamous cell carcinoma , measure area curve ( AUC ) Mouth Throat Soreness ( MTS ) score ( Oral Mucositis Daily Questionnaire [ OMDQ ] question 2 ) measure daily CRT daily 4 week completion CRT . Secondary - To assess whether L. brevis CD2 lozenges reduce OM assess provider use WHO OM scale , Oral Mucositis Assessment Scale ( OMAS ) , Common Terminology Criteria Adverse Events ( CTCAE ) . - To assess whether L. brevis CD2 lozenges reduce impact OM ability swallow , drink , eat , talk , sleep , assess MTS-Activity Limitations ( MTS-AL ) . - To assess whether L. brevis CD2 lozenges improve quality life , assess Functional Assessment Cancer Therapy - Head Neck ( FACT-HN ) . - To assess whether L. brevis CD2 lozenges reduce opioid requirement . - To assess whether L. brevis CD2 lozenges improve radiotherapy compliance . - To assess whether L. brevis CD2 lozenges reduce weight loss need feed tube . - To assess whether L. brevis CD2 lozenges affect disease-free survival ( DFS ) 12 month treatment . - To evaluate effect L. brevis CD2 lozenges salivary biomarkers , include metabonomic inflammatory marker , measure baseline , week 3 CRT , last week CRT . ( exploratory ) OUTLINE : This multicenter , randomize , placebo-controlled , double-blind study . Patients stratify accord primary disease site ( oral cavity/oropharynx v nasopharynx v hypopharynx/larynx ) , context chemoradiotherapy ( CRT ) ( definitive v post-operative ) , cisplatin schedule ( every 3 week [ 100 mg/m^2 ] v every week [ 30-40 mg/m^2 ] ) , use intensity-modulated radiotherapy ( IMRT ) ( yes v ) . Patients randomize 1 2 treatment regimen . - Arm I : Patients dissolve mouth 1 lozenge Lactobacillus brevis CD2 every 2-3 hour ( total 6 per day ) daily CRT ( comprise cisplatin radiotherapy [ RT ] ) 4 week , include weekend . - Arm II : Patients dissolve mouth 1 lozenge placebo every 2-3 hour ( total 6 per day ) daily CRT 4 week , include weekend . Patients complete questionnaire quality life pain baseline daily study treatment . Saliva collect patient start RT , week 3 RT , last week RT NMR-spectroscopic metabolomic analysis future cytokine analysis . After completion study treatment , patient follow 12 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<mesh_term>Body Weight Changes</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologic proof squamous cell carcinoma oral cavity , oropharynx , nasopharynx , hypopharynx , larynx Planned course definitive postoperative radiotherapy ( RT ) total dose ≥ 60 Gy use 1.8 2.0 Gy per fraction At least one third oral cavity mucosa must include RT field , estimate treat radiation oncologist Planned concurrent administration cisplatin chemotherapy ( either 100 mg/m^2 every 3 week 3040 mg/m^2 every week ) PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 0 , 1 , 2 Hemoglobin ≥ 10.0 g/dL White blood cell ( WBC ) ≥ 3,500 x10^9/L Absolute neutrophil count ( ANC ) ≥ 1,500 x10^9/L Platelet count ≥ 100,000 x10^9/L Willing abstain ingestion yogurt product and/or product contain probiotic study drug treatment Ability complete questionnaire ( ) assistance Willing provide saliva sample correlative research purpose ( first 50 patient ) Not pregnant nursing Negative pregnancy test do ≤ 7 day prior registration , woman childbearing potential Men woman childbearing potential must employ adequate contraception No comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimens No current untreated oral candidiasis , oral herpes simplex virus ( HSV ) infection , oral mucositis PRIOR CONCURRENT THERAPY : See Disease Characteristics No splitcourse RT plan No prior head neck RT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>pain</keyword>
	<keyword>oral complication radiation therapy</keyword>
	<keyword>weight change</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage I verrucous carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II verrucous carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IVA squamous cell carcinoma larynx</keyword>
	<keyword>stage IVA squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IVA verrucous carcinoma larynx</keyword>
	<keyword>stage IVB squamous cell carcinoma larynx</keyword>
	<keyword>stage IVB squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IVB verrucous carcinoma larynx</keyword>
	<keyword>stage IVC squamous cell carcinoma larynx</keyword>
	<keyword>stage IVC squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IVC verrucous carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I verrucous carcinoma oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II verrucous carcinoma oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III verrucous carcinoma oral cavity</keyword>
	<keyword>stage IVA squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IVA verrucous carcinoma oral cavity</keyword>
	<keyword>stage IVB squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IVB verrucous carcinoma oral cavity</keyword>
	<keyword>stage IVC squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IVC verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
</DOC>